About Innate Pharma S.A (adapted from Innate Pharma S.A prospectus):
They are a biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. Their ordinary shares are listed on Euronext Paris under the symbol "IPH." The final offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros will be determined through negotiations between them and the representatives of the underwriters for the U.S. offering, and by reference to the prevailing market prices of our ordinary shares on Euronext Paris after taking into account market conditions and other factors. On , 2019, the last reported sale price of our ordinary shares on Euronext Paris was per ordinary share, equivalent to a price of $ per ADS, assuming an exchange rate of 1.00 = $1.1380, the exchange rate on June 28, 2019. The closings of the U.S. offering and the European private placement, which are together referred to as the global offering, will occur substantially simultaneously.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.